Assessing the impact of earlier access to biologics on remission and natural course of asthma (GLEAM)

Study summary

No information provided.

Study identification

• EU PAS number:
  EUPAS1000000530
• Study ID:
  1000000530
• Official title and acronym:
  Assessing the impact of earlier access to biologics on remission and natural course of asthma (GLEAM)
• DARWIN EU® study:
  No
• Study countries:
  Argentina

  Belgium

  Brazil

  Bulgaria

  Canada

  Colombia

  Denmark

  Estonia

  France

  Greece

  India

  Ireland

  Italy

  Japan

  Korea, Republic of

  Kuwait

  Mexico

  Norway

  Poland

  Portugal

  Saudi Arabia

  Singapore

  Spain

  Taiwan

  United Arab Emirates

  United Kingdom

  United States
• Study description:
  An examination of the association between the timing of biologic therapy initiation, disease progression, and remission probabilities in severe asthma.
• Study status:
  Finalised

Research institutions and networks

Institutions

Observational & Pragmatic Research Institute Pte (OPRI)

United Kingdom

Study timelines

Date when funding contract was signed

Planned:17/11/2023

Actual:17/11/2023

Study start date

Planned:01/03/2024

Actual:01/08/2024

Data analysis start date

Actual:15/03/2025

Date of final study report

Planned:21/07/2025

Actual:21/07/2025

Sources of funding

Other

Pharmaceutical company and other private sector 

More details on funding

Pharmaceutical companies: AstraZeneca

Other: Optimum Patient Care Global

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable